Clinical Trial Update: Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of NGR-hTNF as a single agent in colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• NGR-hTNF (NGR-hTNF)

Snippet

Sponsor: AGC Biologics S.p.A. | Conditions: Colorectal Cancer (CRC) | Phase 2 | Status: COMPLETED